Upadacitinib for the Treatment of Atopic Dermatitis

Video

Emma Guttman-Yassky, MD, sits down with Dermatology Times® to discuss recently published results of a phase 3 study evaluating upadacitinib (Rinvoq, AbbVie) as a potential treatment of atopic dermatitis.

Related Videos
Related Content

FDA Issues Complete Response Letter for Lebrikizumab

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Navigating Topical Steroid Withdrawal and Extreme Adverse Reactions to Corticosteroids

September 20th 2023

FDA Issues Complete Response Letter for Lebrikizumab

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Navigating Topical Steroid Withdrawal and Extreme Adverse Reactions to Corticosteroids

September 20th 2023

FDA Issues Complete Response Letter for Lebrikizumab

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Navigating Topical Steroid Withdrawal and Extreme Adverse Reactions to Corticosteroids

September 20th 2023
© 2023 MJH Life Sciences

All rights reserved.